Cullinan Oncology

85 articles about Cullinan Oncology

• Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

  5/25/2023

  Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors.

• Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/11/2023

  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2023.

• Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

  4/26/2023

  Cullinan Oncology, Inc. today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.

• Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

  4/20/2023

  Cullinan Oncology, Inc. today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 2:30 PM EDT.

• Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

  3/27/2023

  Cullinan Oncology, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-617.

• Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

  3/14/2023

  Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.

• Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2022.

• Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

  2/27/2023

  Cullinan Oncology, Inc. today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowen’s 43rd Annual Health Care Conference on March 6, 2023 at 11:10 AM EST.

• Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

  2/14/2023

  Cullinan Oncology, Inc. and Harbour BioMed announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 in the U.S.

• Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

  2/2/2023

  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in the following conferences in February.

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 56,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

• Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  1/24/2023

  Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life.

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 37,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

• Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

  11/14/2022

  Cullinan Oncology, Inc. (Nasdaq: CGEM) a biopharmaceutical company focused on modality-agnostic targeted oncology, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022.

• Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

  11/2/2022

  Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, announced that David P. Ryan, M.D. has been appointed to the company’s Board of Directors.

• Cullinan Oncology to Participate in Upcoming Investor Conferences - November 01, 2022

  11/1/2022

  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, announced that its management team will participate in the following investor conferences.

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022

  11/1/2022

  Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 147,000 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Cullinan Oncology, Inc. announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 242,000 shares of its common stock to seven employees outside Cullinan Oncology, Inc.’s 2021 Stock Option and Incentive Plan.

• Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

  9/7/2022

  Cullinan Oncology, Inc. announced that Company management will participate in the following investor conferences.